Nectar Lifesciences Limited

NSEI:NECLIFE Stock Report

Market Cap: ₹8.2b

Nectar Lifesciences Valuation

Is NECLIFE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NECLIFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NECLIFE (₹36) is trading below our estimate of fair value (₹184.2)

Significantly Below Fair Value: NECLIFE is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NECLIFE?

Other financial metrics that can be useful for relative valuation.

NECLIFE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA9.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does NECLIFE's PE Ratio compare to its peers?

The above table shows the PE ratio for NECLIFE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.9x
524212 Wanbury
16.2xn/a₹8.5b
524075 Albert David
11.1xn/a₹7.8b
INDSWFTLAB Ind-Swift Laboratories
1.6xn/a₹6.6b
SAKAR Sakar Healthcare
54.7xn/a₹6.8b
NECLIFE Nectar Lifesciences
131.4xn/a₹8.2b

Price-To-Earnings vs Peers: NECLIFE is expensive based on its Price-To-Earnings Ratio (131.4x) compared to the peer average (20.9x).


Price to Earnings Ratio vs Industry

How does NECLIFE's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: NECLIFE is expensive based on its Price-To-Earnings Ratio (131.4x) compared to the Indian Pharmaceuticals industry average (37.7x).


Price to Earnings Ratio vs Fair Ratio

What is NECLIFE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NECLIFE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio131.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NECLIFE's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies